Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07461727 | An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases | not yet recruiting | Phase 1 | 15 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Mar 10, 2026 | clinicaltrials |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 626 | Qilu Pharmaceutical Co., Ltd.INDUSTRY |
| 0 |
| Mar 6, 2026 |
| clinicaltrials |
| NCT07442565 | SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ(SYNSTAR03) | not yet recruiting | Phase 3 | 506 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Mar 4, 2026 | clinicaltrials |
| NCT06552000 | Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer | not yet recruiting | N/A | 18 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07423117 | A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy | not yet recruiting | Phase 1 | 102 | IntoCell, IncINDUSTRY | 0 | Feb 20, 2026 | clinicaltrials |
| NCT07418866 | FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 70 | Fudan UniversityOTHER | 0 | Feb 18, 2026 | clinicaltrials |
| NCT07418879 | A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC | not yet recruiting | N/A | 25 | Fudan UniversityOTHER | 0 | Feb 18, 2026 | clinicaltrials |
| NCT07413952 | Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases | not yet recruiting | Phase 2 | 45 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07416058 | PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC(PHOENIX) | not yet recruiting | Phase 2 | 61 | Guangdong Association of Clinical TrialsOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT07410611 | ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy | not yet recruiting | Phase 2 | 84 | Hebei Medical University Fourth HospitalOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07401056 | Preoperative Structured Exercise Programme on Patients With Non-Small Cell Lung Cancer(READY-LUNG) | not yet recruiting | N/A | 62 | Hacettepe UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07400575 | Anlotinib in Cross-line Treatment of NSCLC and SCLC(NSCLC SCLC) | not yet recruiting | — | 350 | Henan Cancer HospitalOTHER_GOV | 0 | Feb 10, 2026 | clinicaltrials |
| NCT07392073 | Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC | not yet recruiting | — | 80 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Feb 6, 2026 | clinicaltrials |
| NCT07393555 | Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial) | not yet recruiting | Phase 2 | 117 | SWOG Cancer Research NetworkNETWORK | 0 | Feb 6, 2026 | clinicaltrials |
| NCT07229339 | Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 16 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07383116 | Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 500 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07383454 | Lung Cancer Screening in Population Who Had Never Smoked | not yet recruiting | N/A | 2,500 | Chung Shan Medical UniversityOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT06638125 | 3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial | not yet recruiting | Phase 1 / Phase 2 | 89 | St. Joseph's Healthcare HamiltonOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07377916 | Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC(NSCLC) | not yet recruiting | N/A | 60 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Jan 30, 2026 | clinicaltrials |
| NCT07376512 | Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis(EVpredict) | not yet recruiting | — | 378 | Centre Georges Francois LeclercOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07373171 | Evaluation of Different Sizes of Left-Sided Double-Lumen Tubes for Thoracic Surgery in a Tertiary Level Teaching Hospital | not yet recruiting | N/A | 60 | Tribhuvan University, NepalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07365410 | Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study | not yet recruiting | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07358884 | First in Human Study of QLS5316 in Solid Tumors | not yet recruiting | Phase 1 | 300 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jan 22, 2026 | clinicaltrials |
| NCT07298148 | Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg | not yet recruiting | Phase 2 | 28 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 21, 2026 | clinicaltrials |
| NCT07351565 | Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer(CPPGPTCLC) | not yet recruiting | Phase 1 | 22 | Chang ChenOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07353476 | Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC | not yet recruiting | Phase 2 | 38 | Shanghai Zhongshan HospitalOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07347977 | Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk(LidCRM) | not yet recruiting | N/A | 1,400 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07343479 | Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases | not yet recruiting | Phase 2 | 45 | Zhejiang Cancer HospitalOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07339839 | Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC | not yet recruiting | Phase 1 / Phase 2 | 42 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jan 14, 2026 | clinicaltrials |
| NCT07318636 | NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC | not yet recruiting | Phase 1 | 10 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07294261 | Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC | not yet recruiting | Phase 2 | 69 | Sun Yat-sen UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07287904 | Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data | not yet recruiting | — | 1,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07285148 | A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer | not yet recruiting | Phase 1 / Phase 2 | 253 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07286942 | Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial | not yet recruiting | Phase 2 | 24 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07281209 | A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 40 | Shanghai Chest HospitalOTHER | 0 | Dec 15, 2025 | clinicaltrials |
| NCT07283198 | A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 160 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 0 | Dec 15, 2025 | clinicaltrials |
| NCT07274384 | Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial(HYPERBOLIC) | not yet recruiting | Phase 2 | 74 | Università Vita-Salute San RaffaeleOTHER | 0 | Dec 10, 2025 | clinicaltrials |
| NCT07271602 | A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer. | not yet recruiting | Phase 2 | 104 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07273279 | ADH1B and ALDH Gene Variants and Lung Cancer Risk(ALDH) | not yet recruiting | — | 100,000 | Kaohsiung Medical UniversityOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT06882174 | This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer(TIME-NSCLC) | not yet recruiting | Phase 2 | 58 | AHS Cancer Control AlbertaOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT07256509 | A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 120 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Dec 5, 2025 | clinicaltrials |
| NCT07268469 | Minimal Residual Disease in Solid Malignancies(IMRD) | not yet recruiting | N/A | 840 | European Institute of OncologyOTHER | 0 | Dec 5, 2025 | clinicaltrials |
| NCT07260227 | Influence of a PSychological Intensive Support Program for Lung Cancer Patients ON Post-operative Outcomes.(IPSILON) | not yet recruiting | N/A | 138 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Dec 3, 2025 | clinicaltrials |
| NCT06400160 | Clinical Trial of TB511 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 12 | Twinpig Biolab, Inc.INDUSTRY | 0 | Nov 25, 2025 | clinicaltrials |
| NCT07234604 | Is 3D Modeling From Non-contrast CT Accurate for Minimally Invasive Lung Segmentectomies ?(3D-LS) | not yet recruiting | — | 50 | University Hospital, Strasbourg, FranceOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07246759 | Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis(NEUTROFLOW) | not yet recruiting | — | 600 | OncoHost Ltd.INDUSTRY | 3 | Nov 24, 2025 | clinicaltrials |
| NCT07242274 | Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC | not yet recruiting | Phase 3 | 472 | JemincareINDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07235306 | Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC | not yet recruiting | Phase 2 | 45 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Nov 19, 2025 | clinicaltrials |
| NCT07231575 | Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC | not yet recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 0 | Nov 18, 2025 | clinicaltrials |
| NCT05393466 | BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 1 / Phase 2 | 30 | Xcovery Holdings, Inc.INDUSTRY | 0 | Oct 7, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 10, 2026source: clinicaltrials